makeplayserrday

[Riggs @RiggsBarstool]

You have to watch this one folks. Just excellent.

[makeplayserrday @makeplayserrday]

@BostonConnr Mayo Maye be Boutte

[makeplayserrday @makeplayserrday]

@LateRoundQB 👏👏

[makeplayserrday @makeplayserrday]

@PhilGalfond @ViktorBlom Would love to call clock on Bruce by screaming “IT’S TIME!!!”

[makeplayserrday @makeplayserrday]

@MntalHlthMatt Thank you

[SAB BIO @SABBantibody]

No serum sickness or anti-drug antibodies! #SAB142's fully-human antibodies garner native recognition, ensuring a seamless #Type1Diabetes #therapeutic experience. GLP toxicology study confirms its a well-tolerated multi-target therapy for #T1D: https://t.co/tUKee5D1db

[SAB BIO @SABBantibody]

SAB-142 takes #T1D treatment to new heights by providing a multi-pathway approach that can be administered as a single #therapeutic. Learn how we're working to change the trajectory of #Type1Diabetes: https://t.co/9OqEtmer1B

[SAB BIO @SABBantibody]

We're revolutionizing Type 1 Diabetes treatment with SAB-142, a fully-human, multi-target anti-thymocyte immunoglobulin treatment for #T1D. Explore the science behind our breakthrough: https://t.co/zscA1u5F81

#SABBio #Innovation #Therapeutics #Immunology #Biopharma

[SAB BIO @SABBantibody]

Discover SAB-142: a breakthrough fully-human anti-thymocyte globulin treatment for #Type1Diabetes (T1D). Clinically validated and effective in delaying T1D onset. Learn more: https://t.co/6opHsPPzvX

#SABBio #Type1Diabetes #Therapeutics #Immunology #Biopharma #Biotech

[SAB BIO @SABBantibody]

Our revolutionary #DiversitAb™ platform transforms disease-fighting. By generating large-scale, high-potency, fully-human immunoglobulins (#hIgGs) across modalities, we are reshaping the field of antibody development. Find out more: https://t.co/O8vtiarml1 #SABBio #Therapeutics

[makeplayserrday @makeplayserrday]

@sc24evr @KremePuffHS @YouTube *evr

[makeplayserrday @makeplayserrday]

@JPaw23 You got this! Have fun!

[SAB BIO @SABBantibody]

#ICYMI: Our Sr. VP of Research, Thomas Luke, MD, presented positive safety & efficacy data of our influenza therapy, #SAB176, last week at ISIRV-AVG. View the presentation & learn about SAB-176's @US_FDA  Breakthrough Therapy & Fast Track Designations: https://t.co/hTz83Xmtb8

[SAB BIO @SABBantibody]

#DiversitAb is a game-changer for the field of #antibody production. We're working to advance this technology to produce potent #humanIgG across multiple modalities. Learn more: https://t.co/zMk5ypysol #SAbBio

[SAB BIO @SABBantibody]

#SABBio's SAB-142 has shown promising results in pre-clinical trials, offering a safer, fully-human immunoglobulin (hIgG) alternative to currently available #therapeutics for Type 1 #Diabetes. Learn more about how we're innovating to improve lives! https://t.co/Wy53W0qPgQ

[SAB BIO @SABBantibody]

Today at the ISIRV-AVG conference, SAB’s Sr. Vice President of Research, Thomas Luke, MD, will present positive safety and efficacy #data from Phase 1 and 2a clinical trials of SAB-176, our fully-human, broadly neutralizing #influenza immunotherapy. More: https://t.co/EDF7HDxdN2

[SAB BIO @SABBantibody]

Our #DiversitAb™ platform revolutionizes the way we fight disease. Its ability to produce large scale fully-human immunoglobulins #hIgGs across multiple modalities is changing the game in antibody development. Learn more:https://t.co/LBuH4hQ0yQ #SABBio #AntibodyDevelopment"

[SAB BIO @SABBantibody]

Our first fully-human anti-thymocyte hpAB therapeutic, #SAB142, can be administered multiple times without causing immune-related adverse reactions. It has potential to impact millions with #Type1Diabetes. Learn more: https://t.co/eFy0dzp9Gs #SABBio #T1D #Immunotherapy

[SAB BIO @SABBantibody]

#SABBio announces positive top-line results from the Phase 3 @nihseed National Institutes of Health’s ACTIV-2 clinical trial that assessed #SAB185 in non-hospitalized people with COVID-19 who were at high risk for severe outcomes: : https://t.co/HWjBtOEVAW

[SAB BIO @SABBantibody]

Unmet medical needs persist in the fight against #CDiff infections. That's where #SABBio comes in with #SAB195, the first-in-class fully-human #polyclonal immunoglobulin treatment designed to reduce CDI recurrence in high-risk patients. Learn more: https://t.co/ZytI6bv2om